This is the assessment of the relative effectiveness of MammaPrint® – Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer


In the MammaPrint report the authors reported the number of events and patients in the analyses, risk difference and hazard ratios. The authors based their conclusion on this data. We have now identified that the absolute numbers that were reported were incorrect. The version below reflects this corrected error.

Below is the documentation provided by the Collaborative Assessment authoring team: